Key Takeaways
- • Fresenius establishes Fresenius Ventures, a corporate venture capital fund with an intended investment volume of more than €200 million over the next five years, targeting early-stage through growth-stage healthcare companies.
- • The fund will focus on investment areas adjacent to Fresenius' existing strategic platforms—BioPharma, MedTech, and Care Provision—including precision nutrition, microbiome research, new modalities, and digital care provision solutions.
- • Fresenius Ventures combines traditional venture capital with medical, regulatory, and operational expertise, providing portfolio companies access to clinical, scientific, and academic networks within the Fresenius healthcare ecosystem.
- • Dr. Thomas Michael Thestrup, formerly of Angelini Ventures, will lead the newly established unit as it executes Fresenius' #FutureFresenius strategic initiative to strengthen innovation capabilities and tap adjacent growth fields.
- • The venture fund represents a strategic expansion of Fresenius' innovation access strategy, enabling early entry into breakthrough healthcare technologies while maintaining alignment with the company's capital allocation framework.
Summary
Fresenius, the German multinational healthcare company, has established Fresenius Ventures, a corporate venture capital fund designed to accelerate access to innovation across the healthcare ecosystem. The fund will deploy more than €200 million in capital over the next five years, investing across early financing rounds through growth-stage companies in sectors adjacent to its core business platforms.
The venture fund targets investment areas including precision nutrition, microbiome research, new modalities, and digital care provision solutions—all areas that align with Fresenius' existing BioPharma, MedTech, and Care Provision strategic platforms. By combining traditional venture capital with in-house medical, regulatory, and operational expertise, Fresenius Ventures provides portfolio companies with differentiated value beyond capital alone. Companies receiving investment gain access to Fresenius' extensive clinical, scientific, and academic networks, as well as operational capabilities within one of Europe's largest private hospital networks.
Michael Sen, CEO of Fresenius, positioned the venture fund as a cornerstone of the company's #FutureFresenius strategic initiative. "Fresenius Ventures is a strategic instrument of #FutureFresenius," Sen stated. "Through targeted investments in promising healthcare innovators, we gain early access to breakthrough technologies, new ideas, and entrepreneurial talent. This step enables us to strengthen our innovation capabilities within the healthcare ecosystem and tap into adjacent growth fields while consistently strengthening Fresenius."
Leadership of the fund has been assigned to Dr. Thomas Michael Thestrup, a healthcare and corporate venture capital specialist who previously served at Angelini Ventures, the international healthcare venture capital arm of Italian industrial group Angelini Industries. Thestrup's appointment underscores Fresenius' commitment to deploying experienced venture capital expertise in identifying and nurturing healthcare innovators. The fund's establishment aligns with Fresenius' disciplined capital allocation approach, ensuring venture investments support broader strategic objectives while maintaining financial discipline.
The venture fund targets investment areas including precision nutrition, microbiome research, new modalities, and digital care provision solutions—all areas that align with Fresenius' existing BioPharma, MedTech, and Care Provision strategic platforms. By combining traditional venture capital with in-house medical, regulatory, and operational expertise, Fresenius Ventures provides portfolio companies with differentiated value beyond capital alone. Companies receiving investment gain access to Fresenius' extensive clinical, scientific, and academic networks, as well as operational capabilities within one of Europe's largest private hospital networks.
Michael Sen, CEO of Fresenius, positioned the venture fund as a cornerstone of the company's #FutureFresenius strategic initiative. "Fresenius Ventures is a strategic instrument of #FutureFresenius," Sen stated. "Through targeted investments in promising healthcare innovators, we gain early access to breakthrough technologies, new ideas, and entrepreneurial talent. This step enables us to strengthen our innovation capabilities within the healthcare ecosystem and tap into adjacent growth fields while consistently strengthening Fresenius."
Leadership of the fund has been assigned to Dr. Thomas Michael Thestrup, a healthcare and corporate venture capital specialist who previously served at Angelini Ventures, the international healthcare venture capital arm of Italian industrial group Angelini Industries. Thestrup's appointment underscores Fresenius' commitment to deploying experienced venture capital expertise in identifying and nurturing healthcare innovators. The fund's establishment aligns with Fresenius' disciplined capital allocation approach, ensuring venture investments support broader strategic objectives while maintaining financial discipline.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.